Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sandra Allen-Bard
Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia
Clinical Journal of Oncology Nursing
Oncology
Related publications
Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells
Clinical Cancer Research
Cancer Research
Oncology
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia
Haematologica
Hematology
Chronic Myelogenous Leukemia
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations
Mathematical Biosciences
Statistics
Genetics
Probability
Molecular Biology
Biochemistry
Applied Mathematics
Microbiology
Simulation
Immunology
Biological Sciences
Medicine
Agricultural
Modeling
Antileukemic Activity of Lysophosphatidic Acid Acyltransferase- Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib
Clinical Cancer Research
Cancer Research
Oncology
Demonstration of Philadelphia Chromosome Negative Abnormal Clones in Patients With Chronic Myelogenous Leukemia During Major Cytogenetic Responses Induced by Imatinib Mesylate
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Chronic Myelogenous Leukemia Molecular Signature
Oncogene
Cancer Research
Genetics
Molecular Biology
Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
